Cetrorelix

證據等級: L5

預測適應症: 10 個

Cetrorelix: From Data-Gap Original Indication to Hypertrichosis (Disease)

One-Sentence Summary

Cetrorelix (DrugBank DB00050) is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses gonadotropin secretion; however, the evidence pack does not record its original approved indication or detailed mechanism of action. The TxGNN model predicts potential benefit for Hypertrichosis (disease) with a 99.98% prediction score, but this ranks as the model's weakest evidence tier — zero clinical trials and zero publications currently support this specific drug-disease link.

Quick Overview

Item	Content
Original Indication	Not available in evidence pack (flagged as data gap)
Predicted New Indication	Hypertrichosis (disease)
TxGNN Prediction Score	99.98%
Evidence Level	L5 (model prediction only)
Finland Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in a structured form (original_moa: [Data Gap]), and the drug's original approved indication is also not recorded in this evidence pack. Based on the repurposing rationale generated for this candidate, Cetrorelix is characterized as an agent that suppresses gonadotropin (LH/FSH) secretion via GnRH receptor antagonism — a pharmacological class typically associated with reproductive endocrinology uses (e.g., controlled ovarian stimulation), though this is not confirmed by the structured original_indications field here.

The proposed link to hypertrichosis rests on the hypothesis that reduced gonadotropin output could indirectly lower androgen-driven hair growth. The evidence pack itself explicitly labels this as a speculative connection with no direct literature or trial support ("無明確機轉關聯…此為推測性連結,無直接文獻或試驗支持"). No clinical trials, ICTRP registrations, or PubMed literature specific to Cetrorelix and hypertrichosis were found in any query performed. This prediction should therefore be treated as an unvalidated model output rather than a mechanistically grounded hypothesis.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

(Note: 20 PubMed records were retrieved for a lower-ranked candidate indication — "malformation syndrome with odontal and/or periodontal component" — but the evidence pack's own rationale identifies these as generic periodontitis research unrelated to Cetrorelix, i.e., keyword-matching noise rather than genuine supporting evidence, and they are excluded here as they do not pertain to the top-ranked indication.)

Finland Market Information

Cetrorelix currently holds no marketing authorizations in this jurisdiction (market status: 未上市 / Not marketed, 0 authorizations on file). No product/license table is available.

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-drug interaction data are all marked as data gaps in this evidence pack; TFDA package insert extraction is listed as a blocking data gap — DG001.)

Conclusion and Next Steps

Decision: Hold

Rationale: This is an L5, model-prediction-only candidate with no supporting clinical trials or literature, and the evidence pack's own rationale flags the drug-disease mechanistic link as speculative. Combined with the absence of original indication, MOA, and safety data, there is insufficient basis to advance this candidate.

To proceed, the following is needed:

TFDA package insert data (warnings/contraindications) — currently a blocking gap (DG001)
Confirmed mechanism of action and original approved indication (DG002)
Preclinical or mechanistic studies linking GnRH antagonism to hair follicle/androgen pathways in hypertrichosis
Any real-world DDI dataset (current query returned "not_found")
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.